Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Biohaven Ltd.NYSE: BHVN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $100.81M fell 45.3% year over year, behind the -32.9% change in trailing-twelve-month research & development. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -45.3% toward the trailing-twelve-month pace of -32.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$100.81M-2.9% QoQ
Last fiscal yearDec 2025
$635.07M-20.2% YoY
LTMJun 2026
$467.76M-32.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.3%——
1 year-20.2%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
635.07M USD
Year-over-year change
-20.2%
4-year CAGR
+36.8%

Research & Development vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.9% is the lowest of 11, against a peer median of +21.7%.
  • Over three fiscal years its annual growth of +13.3% compares with a peer median of +31.9%.
BHVN Competitors
Research & Development for BHVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$467.76M USD-32.9%+13.3%—
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M USD-21.5%-2.5%546.5%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$360.26M USD+137.9%+38.9%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$283.32M USD+31.2%+43.9%252960.7%
VERAVera Therapeutics, Inc.LTM Jun 2026$261.87M USD+51.3%+45.5%—
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
IMNMImmunome, Inc.LTM Sep 2026$236.54M USD+35.6%+95.7%—
ABCLAbCellera Biologics Inc.LTM Sep 2026$186.28M USD+1.9%+20.1%274.5%
PHVSPharvaris N.V.LTM Sep 2026€132.22M EUR+7.0%+29.5%—
SIONSionna Therapeutics, Inc.LTM Mar 2026$65.56M USD+7.9%+20.3%—
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$32.2M USD+26.3%+14.1%10.2%
Peer median (excluding BHVN) —+21.7%+31.9%274.5%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.